Company: SMNR
Filing Date: 2025-07-23
Form Type: S-4/A
Source: 0001193125-25-163401
Chunk: 1078

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-07-23
Form: S-4/A
Chunk 1078
---
AMED “SEMNUR PHARMACEUTICALS, INC.” IN CONNECTION WITH THE BUSINESS COMBINATION DESCRIBED HEREIN**</div>

This prospectus covers the resale by the selling stockholders as described in the section titled “Selling Stockholders” (collectively, the “Selling Stockholders”) of up to 201,118,000 shares of New Semnur Common Stock (the “Resale Shares”). The Selling Stockholders may sell all, some or none of the Resale Shares. New Semnur will not receive any proceeds from any such offer or sale by the Selling Stockholders.

Denali is a Cayman Islands exempted company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business transaction with one or more businesses or entities, which we refer to as a “target business.” Holders of Class A ordinary shares, par value $0.0001 per share, of Denali (“Denali Class A Ordinary Shares”) and holders of Class B ordinary shares, par value $0.0001 per share, of Denali (“Denali Class B Ordinary Shares”), voting together as a single class, will be asked to approve and adopt the Agreement and Plan of Merger, dated as of August 30, 2024 (as it may be amended or restated from time to time in accordance with its terms, including by Amendment No. 1 to Agreement and Plan of Merger, dated as of April 16, 2025, ( “Amendment No. 1 to Merger Agreement”) and Amendment No. 2 to Agreement and Plan of Merger, dated as of July 22, 2025, (“Amendment No. 2 to Merger Agreement”), the “Merger Agreement”), by and among Denali, Denali Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Denali (the “Merger Sub”), and Semnur Pharmaceuticals, Inc., a Delaware corporation (“Semnur”) and a majority owned subsidiary of Scilex Holding Company (“Scilex”), and the other related proposals described in the proxy statement/prospectus. Copies of the Merger Agreement, Amendment No. 1 to Merger Agreement and Amendment No. 2 to Merger Agreement are attached to this proxy statement/prospectus as Annex A-1, Annex A-2 and Annex A-3, respectively.

Pursuant to the